What will the sales be? For the quarter ended Sept the company reported 44 million from the sales of Lovenox. That was for only 9 weeks of a 13 week quarter. It has also been posted that the 44 is less 35 mil due to development costs paid to its partner.
I confirmed this information in the 10Q foot notes. The 44 mil was net after a 35 mil one time reimbursement for development costs. So Lovenox earnings for the nine weeks was a normalized 79 million. Scripts written in forth quarter will be 3x that of the startup 3Q. Expect 227 mil for the 4th quarter or 4.54 per share from Lovenox.
When this becomes common knowledge expect share price to double. If Copexone is approved in the next few days expect price to double again.!!!!
Market Data 
Markets 
AI
